AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

maura169
Nov 20, 2019
1 min read

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.

READ FULL ARTICLE

Recent Posts

See All

Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC

Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer

Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Recent Posts

Komentarze

Activating the Immune System to Fight Disease

Contact

Sitemap